Primjena odabranih blokatora beta-adrenoreceptora u terapiji kroničnog zatajenja srca

Professional paper - Professional paper

• Author: Marin Vučić
• Author: Lidija Bach-Rojecky
• Author: Maja Ortner Hadžiabdić
• Author's institution: University of Zagreb; Faculty of Pharmacy and Biochemistry; (Centre for applied pharmacy)
• Author's institution: University of Zagreb; Faculty of Pharmacy and Biochemistry; (Department of pharmacology)
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Pharmacy; Pharmacy

Abstract (english)

Heart failure is a clinical syndrome characterized by typical signs
and symptoms ( e.g. breathlessness, ankle swelling, fatigue, elevated
jungular venous pressure) caused by a structural and/or functional cardiac
abnormality. 1he goals of treatment in patients with HF are to improve their
clinical status, functional capacity and quality of life, prevent hospital admission
and reduce mortality. Neurohormonal antagonists (ACE inhibitors, mineralcorticoid
receptor antagonists and beta-blockers) have been shown to improve
survival in patients with heart failure with reduced ejection fraction and are
recommended for the treatment of every patient, unless contraindicated or not
tolerated. Therefore, beta-blockers, although primarily developed and used as
antihypertensive and antianginal drugs, became important therapy in heart failure
management. The evidence of clinical benefit on beta-blockers in patients
with chronic heart failure was demonstrated in a number of small studies and in
several, large, prospective, randomised, placebo-controlled trials and highlighted
four beta-blockers: nebivolol, carvedilol, bisoprolol and metoprolol. This
work reviews the pharmacologic characteristics of beta-blockers and their role
in heart failure as well as clinical evidence on their effectiveness in patients with
heart failure.

• Keywords (croatian): kronično zatajenje srca; blokatori beta-adrenoreceptora; beta blokatori
• Language: croatian
• Publication type: Professional paper - Professional paper
• Publication status: Published
• Peer review: Peer review - domestic
• Publication version: Published version
• Journal title: Farmaceutski glasnik
• Numbering: vol. 75, no. 5, pp. 357-369
• p-ISSN: 0014-8202
• URN:NBN: urn:nbn:hr:163:877535
• Publication: 2019
• Type of resource: Text
• Access conditions: Open access
• Created on: 2020-06-08 08:47:32